On October 28, 2026, Shanghai Jiahui International Hospital announced globally via PRNewswire the official launch of the Jiahui International Cell Therapy Center. Positioned as a standardized clinical application platform connecting China's cell therapy innovation with global patients, the Center complements the research translation pathway led by Grade-3A hospitals — where top-tier hospitals focus on clinical trials and publications, Jiahui focuses on standardizing international clinical application.
Since operations began, the Center has served CAR-T patients from Singapore, Hong Kong, Russia, Hungary, New Zealand, India, Pakistan and the Maldives, covering both hematologic and solid tumors. Xiang Naiqiang, a member of Jiahui's executive committee, noted that cell therapy has become one of Shanghai's most competitive medical offerings for international patients.
For international patients, access to frontier therapies such as solid-tumor CAR-T is a key factor in choosing a treatment destination. As one of the few Chinese institutions with both cell therapy credentials and an international patient service system, Jiahui offers twelve-language medical coordination, international medical record review and standardized follow-up; integration with cross-border platforms like MedBridge further lowers communication and process costs for overseas patients.
How MedBridge Shanghai Helps
As a leading cross-border medical platform in Shanghai, MedBridge Shanghai provides end-to-end support: free medical record review and specialist appointments, pre-travel coordination and visa support, airport pickup and accommodation, full medical interpretation and coordination, and post-treatment follow-up with remote consultations.
For more information on CAR-T treatment options and costs, contact our medical advisors, or explore our medical services and partner hospitals.
[Disclaimer] This article is not medical advice. Indications, costs and availability of cell therapy must be confirmed by in-person physician evaluation and the hospital's official plan.